Physician profile
Gary E Johnson
NPI 1508868233
$14,289.36
in general payments reported to CMS, 2019-2025
31 companies · $20.10 in 2025
The $20.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,618 · 2020: $1,276 · 2021: $1,648 · 2022: $8,681 · 2023: $45.47 · 2025: $20.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $8,055.09 | 2022 | |
| Glaxosmithkline, LLC. | $850.71 | 2019-2022 | |
| Abbvie INC. | $726.88 | 2019-2023 | |
| Novo Nordisk INC | $716.86 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $615.70 | 2019-2022 | |
| Lilly USA, LLC | $488.37 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.46 | 2019-2022 | |
| Pfizer INC. | $405.24 | 2019-2021 | |
| Amarin Pharma, INC. | $339.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $280.19 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.10 | 2019-2021 | |
| Allergan, INC. | $198.79 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $180.75 | 2019-2021 | |
| Daiichi Sankyo INC. | $128.51 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $109.88 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $76.78 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $50.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.46 | 2019-2020 | |
| Gilead Sciences, INC. | $28.92 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $26.11 | 2022 | |
| Vertical Pharmaceuticals, LLC | $25.75 | 2019 | |
| Eisai INC. | $25.24 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $18.61 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.05 | 2020 | |
| Currax Pharmaceuticals LLC | $15.57 | 2021 | |
| Tactile Systems Technology INC | $14.49 | 2019 | |
| Advanced Respiratory, INC | $13.18 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.51 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.32 | 2020 | |
| Scilex Pharmaceuticals INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.